Gene P. Siegal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gene P. Siegal has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Shi Wei
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
4 shared publications - Kui Zhang
Department of Mathematical Sciences Michigan Technological University Houghton MI USA
2 shared publications Shi Wei
From the Departments of Pathology and Genetics, University of Alabama at Birmingham
2 shared publications- Shuko Harada
Division of Genomic Diagnostics and Bioinformatics, Department of Pathology, University of Alabama at Birmingham , Birmingham, AL
2 shared publications - Ahmed Elkhanany
University of Alabama at Birmingham, Birmingham, USA
1 shared publication - Akseli Hemminki
Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
1 shared publication
Latest Publications
- 1 April 2024
- Published by SAGE Publications in Tissue Engineering Part A
- Vol. 30 (7-8) , 357-366
Continuous Low-Intensity Ultrasound Improves Cartilage Repair in Rabbit Model of Subchondral Injury
Subchondral drilling (SD), a bone marrow stimulation technique, is used to repair cartilage lesions that lack regenerative potential. Cartilage repair outcomes upon SD are typically fibrocartilaginous in nature with inferior functionality. The lack of cues to foster the chondrogenic differentiation of egressed mesenchymal stromal cells (MSCs) upon SD, can be attributed for the poor outcomes. Continuous low-intensity ultrasound (cLIUS) at 3.8 MHz is proposed as a treatment modality for improving cartilage repair outcomes upon marrow stimulation. Bilateral defects were created via SD on the femoral medial condyle of female New Zealand white rabbits (n=12) and the left joint received cLIUS treatment (3.8 MHz, 3.5 Vpp, 8 minutes/application/day) and the contralateral right joint served as the control. On day-7 post surgery, synovial fluid was aspirated and the cytokine levels were assessed by Quantibody™ assay. Rabbits were euthanized at 8-weeks and outcomes were assessed macroscopically and histologically. Defect areas in the right joints exhibited boundaries, incomplete fill, irregular cartilage surfaces, loss of glycosaminoglycan (GAG), and absence of chondrocytes. In contrast, the repaired defect area in the joints that received cLIUS showed complete fill, positive staining for GAG with rounded chondrocyte morphology, COL2A1 staining and columnar organization. Synovial fluid collected from cLIUS treated left knee joints had lower levels of IL1, TNFα and IFNγ when compared to untreated right knee joints, alluding to the potential of cLIUS to mitigate early inflammation. Further at 8-weeks, left knee joints (n=12) consistently scored higher on the O”Driscoll scale; with a higher % hyaline cartilage score. No adverse impact on bone or change in the joint space was noted. Upon a single exposure of cLIUS to TNFα treated cells, nuclear localization of pNFκB and SOX9 was visualized by double immunofluorescence and the expression of markers associated with the NFκB pathway was assayed by qRT-PCR. cLIUS extends its chondroprotective effects by titrating pNFκB levels, preventing its nuclear translocation while maintaining the expression of SOX9, the collagen II transcription factor. Our combined results demonstrate that healing of chondral defects treated with marrow stimulation via SD can be accelerated by employing cLIUS regimen that possess chondroinductive and chondroprotective properties.
- 1 April 2024
- Published by SAGE Publications in Tissue Engineering Part A
- Vol. 30 (7-8) , 357-366
Continuous Low-Intensity Ultrasound Improves Cartilage Repair in Rabbit Model of Subchondral Injury
Subchondral drilling (SD), a bone marrow stimulation technique, is used to repair cartilage lesions that lack regenerative potential. Cartilage repair outcomes upon SD are typically fibrocartilaginous in nature with inferior functionality. The lack of cues to foster the chondrogenic differentiation of egressed mesenchymal stromal cells (MSCs) upon SD, can be attributed for the poor outcomes. Continuous low-intensity ultrasound (cLIUS) at 3.8 MHz is proposed as a treatment modality for improving cartilage repair outcomes upon marrow stimulation. Bilateral defects were created via SD on the femoral medial condyle of female New Zealand white rabbits (n=12) and the left joint received cLIUS treatment (3.8 MHz, 3.5 Vpp, 8 minutes/application/day) and the contralateral right joint served as the control. On day-7 post surgery, synovial fluid was aspirated and the cytokine levels were assessed by Quantibody™ assay. Rabbits were euthanized at 8-weeks and outcomes were assessed macroscopically and histologically. Defect areas in the right joints exhibited boundaries, incomplete fill, irregular cartilage surfaces, loss of glycosaminoglycan (GAG), and absence of chondrocytes. In contrast, the repaired defect area in the joints that received cLIUS showed complete fill, positive staining for GAG with rounded chondrocyte morphology, COL2A1 staining and columnar organization. Synovial fluid collected from cLIUS treated left knee joints had lower levels of IL1, TNFα and IFNγ when compared to untreated right knee joints, alluding to the potential of cLIUS to mitigate early inflammation. Further at 8-weeks, left knee joints (n=12) consistently scored higher on the O”Driscoll scale; with a higher % hyaline cartilage score. No adverse impact on bone or change in the joint space was noted. Upon a single exposure of cLIUS to TNFα treated cells, nuclear localization of pNFκB and SOX9 was visualized by double immunofluorescence and the expression of markers associated with the NFκB pathway was assayed by qRT-PCR. cLIUS extends its chondroprotective effects by titrating pNFκB levels, preventing its nuclear translocation while maintaining the expression of SOX9, the collagen II transcription factor. Our combined results demonstrate that healing of chondral defects treated with marrow stimulation via SD can be accelerated by employing cLIUS regimen that possess chondroinductive and chondroprotective properties.
- 20 June 2023
- Published by Elsevier in Journal of Orthopaedic Science
- Vol. 29 (2) , 690-694
An Aneurysmal bone cyst harboring a novel ACSL4::USP6 fusion gene
- 20 June 2023
- Published by Elsevier in Journal of Orthopaedic Science
- Vol. 29 (2) , 690-694
An Aneurysmal bone cyst harboring a novel ACSL4::USP6 fusion gene
- Open Access
Mutations in Homologous Recombination Genes and Loss of Heterozygosity Status in Advanced-Stage Breast Carcinoma
Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPis) have demonstrated antitumor activity in cancers with a homologous recombination deficiency (HRD) and have recently been approved by the FDA for the treatment of germline BRCA1/2-mutation-associated breast cancer. PARPis have also been found to be efficacious in BRCA wild-type (BRCAwt) lesions with high genomic loss of heterozygosity (LOH-high). The goal of this study was to retrospectively investigate the tumor mutations in homologous recombination (HRR) genes and the LOH score in advanced-stage breast carcinomas (BCs). Sixty-three patients were included in our study, 25% of whom had HRR gene mutations in their tumors, including 6% BRCA1/2 and 19% non-BRCA-containing gene mutations. An HRR gene mutation was associated with a triple-negative phenotype. Twenty-eight percent of the patients had an LOH-high score, which, in turn, was associated with a high histological grade, a triple-negative phenotype, and a high tumor mutational burden (TMB). Among the six patients who received PARPi therapy, one had a tumor with a PALB2 mutation other than BRCA and had a clinical partial response. Twenty-two percent of the LOH-low tumors had BRCAwt–HRR gene mutations, compared with 11% of the LOH-high tumors. Comprehensive genomic profiling revealed a subset of breast cancer patients with a BRCAwt–HRR gene mutation that would be missed by an LOH test. The necessity of next-generation sequencing coupled with HRR gene analysis for PARPi therapy requires further investigation in clinical trials.
Open AccessMutations in Homologous Recombination Genes and Loss of Heterozygosity Status in Advanced-Stage Breast Carcinoma
Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPis) have demonstrated antitumor activity in cancers with a homologous recombination deficiency (HRD) and have recently been approved by the FDA for the treatment of germline BRCA1/2-mutation-associated breast cancer. PARPis have also been found to be efficacious in BRCA wild-type (BRCAwt) lesions with high genomic loss of heterozygosity (LOH-high). The goal of this study was to retrospectively investigate the tumor mutations in homologous recombination (HRR) genes and the LOH score in advanced-stage breast carcinomas (BCs). Sixty-three patients were included in our study, 25% of whom had HRR gene mutations in their tumors, including 6% BRCA1/2 and 19% non-BRCA-containing gene mutations. An HRR gene mutation was associated with a triple-negative phenotype. Twenty-eight percent of the patients had an LOH-high score, which, in turn, was associated with a high histological grade, a triple-negative phenotype, and a high tumor mutational burden (TMB). Among the six patients who received PARPi therapy, one had a tumor with a PALB2 mutation other than BRCA and had a clinical partial response. Twenty-two percent of the LOH-low tumors had BRCAwt–HRR gene mutations, compared with 11% of the LOH-high tumors. Comprehensive genomic profiling revealed a subset of breast cancer patients with a BRCAwt–HRR gene mutation that would be missed by an LOH test. The necessity of next-generation sequencing coupled with HRR gene analysis for PARPi therapy requires further investigation in clinical trials.
- 13 January 2023
- Published by Elsevier in Laboratory Investigation
- Vol. 103 (3) , 100065
Gratitude and a Warning
- 13 January 2023
- Published by Elsevier in Laboratory Investigation
- Vol. 103 (3) , 100065
Gratitude and a Warning
- 28 April 2022
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 60, 151957
The diagnostic utility of RNA-based fusion panel testing ordered by pathologists in challenging cases
- 28 April 2022
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 60, 151957
The diagnostic utility of RNA-based fusion panel testing ordered by pathologists in challenging cases
- 1 December 2021
- Published by Elsevier in Laboratory Investigation
- Vol. 34 (12) , 2141-2147
A simplified breast cancer prognostic score: comparison with the AJCC clinical prognostic staging system
- 1 December 2021
- Published by Elsevier in Laboratory Investigation
- Vol. 34 (12) , 2141-2147
A simplified breast cancer prognostic score: comparison with the AJCC clinical prognostic staging system
- Open Access
- 4 May 2021
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 146 (1) , 60-69
Some Reactive Lesions of Bone Are Probably Neoplasms
Context.—: A number of fibro-osseous and osteocartilaginous lesions, especially common in the small bones of the hand and feet, pose a diagnostic challenge and have historically been thought to be reactive lesions. However, modern molecular techniques when supplementing clinical, radiographic, and histologic evaluation suggest they may, in fact, be neoplasms. Objective.—: To review the clinical presentation and histopathologic, molecular, and radiologic features of selective bone lesions, focusing most specifically on subungual exostosis, florid reactive periostitis, and bizarre periosteal osteochondromatous proliferation. Data Sources.—: Literature review and personal experience are the sources of this review. Conclusions.—: Some lesions previously thought to be reactive are locally aggressive and demonstrate reproducible molecular abnormalities, and thus may be neoplasms. Although most common in the bones of the fingers and toes, these lesions also occur in long and other bones. The clinical presentations, radiologic appearances, and histopathologic features often overlap, making the diagnosis challenging, and these lesions may require molecular evaluation to maximize accurate prognostication.
- 4 May 2021
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 146 (1) , 60-69
Open AccessSome Reactive Lesions of Bone Are Probably Neoplasms
Context.—: A number of fibro-osseous and osteocartilaginous lesions, especially common in the small bones of the hand and feet, pose a diagnostic challenge and have historically been thought to be reactive lesions. However, modern molecular techniques when supplementing clinical, radiographic, and histologic evaluation suggest they may, in fact, be neoplasms. Objective.—: To review the clinical presentation and histopathologic, molecular, and radiologic features of selective bone lesions, focusing most specifically on subungual exostosis, florid reactive periostitis, and bizarre periosteal osteochondromatous proliferation. Data Sources.—: Literature review and personal experience are the sources of this review. Conclusions.—: Some lesions previously thought to be reactive are locally aggressive and demonstrate reproducible molecular abnormalities, and thus may be neoplasms. Although most common in the bones of the fingers and toes, these lesions also occur in long and other bones. The clinical presentations, radiologic appearances, and histopathologic features often overlap, making the diagnosis challenging, and these lesions may require molecular evaluation to maximize accurate prognostication.
- 10 August 2020
- Published by Elsevier in Laboratory Investigation
- Vol. 34 (2) , 291-299
Validation of the revised 8th AJCC breast cancer clinical prognostic staging system: analysis of 5321 cases from a single institution
- 10 August 2020
- Published by Elsevier in Laboratory Investigation
- Vol. 34 (2) , 291-299
Validation of the revised 8th AJCC breast cancer clinical prognostic staging system: analysis of 5321 cases from a single institution
- 3 July 2020
- Published by Elsevier in Laboratory Investigation
- Vol. 33 (12) , 2499-2506
Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution
- 3 July 2020
- Published by Elsevier in Laboratory Investigation
- Vol. 33 (12) , 2499-2506
Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution
- 1 May 2020
- Published by Elsevier in The American Journal of Pathology
- Vol. 190 (5) , 918-933
Return of Individual Research Results
- 1 May 2020
- Published by Elsevier in The American Journal of Pathology
- Vol. 190 (5) , 918-933
Return of Individual Research Results